A5033335386- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- SARS-CoV-2 detection and testing
- COVID-19 epidemiological studies
- COVID-19 and healthcare impacts
- Innovations in Medical Education
- Viral gastroenteritis research and epidemiology
- Bacterial Infections and Vaccines
- Immune responses and vaccinations
- Viral Infections and Outbreaks Research
- Antibiotic Resistance in Bacteria
- Influenza Virus Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- Bacillus and Francisella bacterial research
- Respiratory viral infections research
- Pneumonia and Respiratory Infections
- Nail Diseases and Treatments
- Tuberculosis Research and Epidemiology
- Pharmaceutical Practices and Patient Outcomes
- Patient-Provider Communication in Healthcare
- Drug-Induced Adverse Reactions
- Health and Medical Research Impacts
- Long-Term Effects of COVID-19
- Antibiotic Use and Resistance
Hamad Medical Corporation
2016-2025
Qatar University
2016-2025
Weill Cornell Medical College in Qatar
2017-2025
Hôpital de Jolimont
2022
University Hospitals Coventry and Warwickshire NHS Trust
2022
Hamad General Hospital
2004-2020
Office of Education
2016
University of Illinois Chicago
2016
National Taiwan University
2016
New York Hospital Queens
2016
The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of omicron (B.1.1.529) variant is unclear.
Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence omicron (or B.1.1.529) variant severe acute respiratory syndrome 2 (SARS-CoV-2) have led to expedited efforts scale up booster vaccination. Protection conferred by doses BNT162b2 (Pfizer–BioNTech) mRNA-1273 (Moderna) vaccines in Qatar, as compared with two-dose primary series, is unclear.
Abstract SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection the second third/booster doses mRNA COVID-19 vaccines against infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4–57.2%) symptomatic 51.7% 43.2–58.9%) first three months after dose, but declined ~10% or below thereafter. Effectiveness rebounded 59.9% 51.2–67.0%) 43.7% 36.5–50.0%), respectively,...
Vaccine hesitancy is a global threat undermining control of preventable infections. Emerging evidence suggests that to COVID-19 vaccination varies globally. Qatar has unique population with around 90% the being economic migrants, and degree determinants are not known.This study was carried out evaluate vaccine its socio-demographic attitudinal across representative sample. A national cross-sectional using validated measurement tool from October 15, 2020, November 2020. total 7821 adults...
Abstract Background The future of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic hinges on virus evolution and duration immune protection natural infection against reinfection. We investigated afforded by infection, effect viral evasion reinfection, in Qatar, between 28 February 2020 5 June 2022. Methods Three national, matched, retrospective cohort studies were conducted to compare incidence SARS-CoV-2 disease 2019 (COVID-19) severity among unvaccinated persons...
Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved over short timescales, leading to the emergence of more transmissible variants such as Alpha and Delta 1–3 . arrival Omicron variant marked a major shift, introducing numerous extra mutations in spike gene compared with earlier 1,2 These evolutionary changes have raised concerns regarding their potential impact on immune evasion, disease severity effectiveness vaccines treatments 1,3 In this...
Background: The ongoing pandemic of SARS-COV-2 has already infected more than eight million people worldwide. majority COVID-19 patients either are asymptomatic or have mild symptoms. Yet, about 15% the cases experience severe complications and require intensive care. Factors determining disease severity not yet fully characterized. Aim: Here, we investigated within-host virus diversity in with different clinical manifestations. Methods: We compared genetic 19 27 cases. Viral RNA was...
Abstract SARS-CoV-2 breakthrough infections in vaccinated individuals and those who had a prior infection have been observed globally, but the transmission potential of these is unknown. The RT-qPCR cycle threshold (Ct) value inversely correlated with viral load culturable virus. Here, we investigate differences Ct values across Qatar’s national cohorts primary infections, reinfections, BNT162b2 (Pfizer-BioNTech) mRNA-1273 (Moderna) infections. Our matched-cohort analyses randomly diagnosed...
Abstract There is significant genetic distance between SARS-CoV-2 Omicron (B.1.1.529) variant BA.1 and BA.2 sub-lineages. This study investigates immune protection of infection with one sub-lineage against reinfection the other in Qatar during a large wave, from December 19, 2021 to March 21, 2022. Two national matched, retrospective cohort studies are conducted estimate effectiveness (N = 20,994; BA.1-against-BA.2 study), 110,315; BA.2-against-BA.1 study). Associations estimated using Cox...
BackgroundWe investigated the clinical characteristics and risk factors for isolation of multi-drug-resistant (MDR) Gram-negative bacteria (GNB) from critically ill COVID-19 patients.MethodsWe retrospectively matched (1:2) critical patients with one or more MDR GNB any specimen (cases), those no isolates (controls).ResultsSeventy-eight cases were identified (4.5 per 1000 intensive care unit (ICU) days, 95% confidence interval (CI) 3.6–5.7). Of 98 isolates, most frequent species...
Qatar, a country with strong health system and diverse population consisting mainly of expatriate residents, has experienced two large waves COVID-19 outbreak. In this study, we report on 2634 SARS-CoV-2 whole-genome sequences from infected patients in Qatar between March-2020 March-2021, representing 1.5% all positive cases period. Despite the restrictions international travel, viruses sampled populace mirrored nearly entire global population's genomic diversity nine predominant viral...
The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 17 but different antigen doses.We assessed the real-world effectiveness infection with severe acute respiratory syndrome 2 (SARS-CoV-2) among Qatar. To compare incidence SARS-CoV-2 national cohort vaccinated participants unvaccinated participants, we conducted three matched, retrospective, target-trial, studies - one assessing data obtained from...
BACKGROUND: Protection offered by five different forms of immunity, combining natural and vaccine was investigated against SARS-CoV-2 Omicron symptomatic BA.1 infection, BA.2 hospitalization death, in Qatar, between December 23, 2021 February 21, 2022. METHODS: Six national, matched, test-negative case-control studies were conducted to estimate effectiveness BNT162b2 (Pfizer-BioNTech) vaccine, mRNA-1273 (Moderna) immunity due prior infection with pre-Omicron variants, hybrid from...
Protection against SARS-CoV-2 symptomatic infection and severe COVID-19 of previous infection, mRNA two-dose vaccination, three-dose hybrid immunity vaccination were investigated in Qatar for the Alpha, Beta, Delta variants.
Objective To investigate all-cause mortality, COVID-19 mortality and non-COVID-19 in Qatar during the pandemic. Methods A national, retrospective cohort analysis matched, studies were conducted between 5 February 2020 19 September 2022. Results There 5025 deaths a follow-up time of 247 220 person-years, which 675 related. Incidence rates 0.96 (95% CI 0.93 to 0.98) per 1000 person-years for 0.13 0.12 0.14) 0.83 0.80 0.85) mortality. Adjusted HR, comparing relative Qataris, was lowest Indians...
Overall effectiveness of infection in preventing reinfection with SARS-CoV-2 JN.1 variant was estimated at 1.8% (95% CI: −9.3to 12.6%), and demonstrated rapid decline over time since the previous infection, decreasing from 82.4% 40.9 to 94.7%) within 3 less than 6 months, a negligible level after one year.
There are limited data on Coronavirus Disease 2019 (COVID-19) outcomes at a national level, and none after 60 days of follow up. The aim this study was to describe national, 60-day all-cause mortality associated with COVID-19, identify risk factors admission an intensive care unit (ICU).
Zion Congrave-Wilson, MS; Yesun Lee, PhD; Jaycee Jumarang, MD; Stephanie Perez, BS; Jeffrey M. Bender, Jennifer Dien Bard, Pia S. Pannaraj, MD, MPH
Compared to BA.1, BA.2 was associated with lower RT-qPCR cycle threshold (Ct) value-3.53fewer cycles (95% CI: 3.46-3.60),signifying higher infectiousness.This may reflect viral load and/or longer duration of infection for BA.2.Natural immunity from previous and booster vaccination were less infectious breakthrough infections.